NASDAQ:DSGN

Design Therapeutics (DSGN) Stock Price, News & Analysis

$3.66
0.00 (0.00%)
(As of 03:28 PM ET)
Today's Range
$3.55
$3.73
50-Day Range
$2.32
$4.03
52-Week Range
$1.94
$8.47
Volume
140,633 shs
Average Volume
261,822 shs
Market Capitalization
$206.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Design Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
50.3% Upside
$5.50 Price Target
Short Interest
Bearish
6.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$99,750 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.26) to ($1.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.35 out of 5 stars

Medical Sector

716th out of 909 stocks

Pharmaceutical Preparations Industry

331st out of 423 stocks

DSGN stock logo

About Design Therapeutics Stock (NASDAQ:DSGN)

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

DSGN Stock Price History

DSGN Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
RBC Capital Reaffirms Their Hold Rating on Design Therapeutics (DSGN)
One trade. One ticker. One week.
Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week?
Design Therapeutics Inc (DSGN)
Earnings Preview For Design Therapeutics
DSGN Apr 2024 7.500 put
DSGN Jul 2024 2.500 put
SR ONE CAPITAL PARTNERS I, LP's Net Worth
Design Therapeutics Inc DSGN
Design Therapeutics (NASDAQ: DSGN)
See More Headlines
Receive DSGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/19/2024
Today
4/24/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DSGN
Fax
N/A
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+50.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
7 Analysts

Profitability

Net Income
$-66,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.96 per share

Miscellaneous

Free Float
41,975,000
Market Cap
$206.75 million
Optionable
Optionable
Beta
1.82
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Pratik Shah Ph.D. (Age 54)
    Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson
    Comp: $638.46k
  • Dr. Sean Jeffries Ph.D. (Age 44)
    Chief Operating Officer
    Comp: $572.21k
  • Dr. Aseem Z. Ansari Ph.D.
    Co-Founder & Scientific Advisor
  • Ms. Julie D. Burgess CPA
    Chief Accounting Officer
  • Dr. Jae B. Kim FACC (Age 54)
    M.D., Chief Medical Officer
  • Ms. Dawn Giangiulio
    Controller

DSGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Design Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" DSGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSGN, but not buy additional shares or sell existing shares.
View DSGN analyst ratings
or view top-rated stocks.

What is Design Therapeutics' stock price target for 2024?

7 equities research analysts have issued 12-month target prices for Design Therapeutics' stock. Their DSGN share price targets range from $4.00 to $6.00. On average, they expect the company's share price to reach $5.50 in the next year. This suggests a possible upside of 50.3% from the stock's current price.
View analysts price targets for DSGN
or view top-rated stocks among Wall Street analysts.

How have DSGN shares performed in 2024?

Design Therapeutics' stock was trading at $2.65 on January 1st, 2024. Since then, DSGN shares have increased by 38.1% and is now trading at $3.66.
View the best growth stocks for 2024 here
.

When is Design Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our DSGN earnings forecast
.

How were Design Therapeutics' earnings last quarter?

Design Therapeutics, Inc. (NASDAQ:DSGN) announced its quarterly earnings data on Tuesday, March, 19th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.11.

When did Design Therapeutics IPO?

Design Therapeutics (DSGN) raised $228 million in an initial public offering on Friday, March 26th 2021. The company issued 12,000,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

Who are Design Therapeutics' major shareholders?

Design Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BML Capital Management LLC (1.56%) and Assenagon Asset Management S.A. (0.62%). Insiders that own company stock include Arsani William, Deepa Prasad, Joao Md Siffert, John P Schmid, Rodney W Lappe, Simeon George, Sr One Capital Fund I Aggregat and Stella Xu.
View institutional ownership trends
.

How do I buy shares of Design Therapeutics?

Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DSGN) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners